Lack of β2-AR improves exercise capacity and skeletal muscle oxidative phenotype in mice

Scandinavian Journal of Medicine and Science in Sports

Volumn 22, Issue 6, 2012, Pages

  Voltarelli, V A ^a   Bacurau, A V N ^a   Bechara, L R G ^a   Bueno Junior C R ^a   Bozi, L H M ^a   Mattos, K C ^a   Salemi, V M C ^a   Brum, P C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

2 adrenergic receptors; Endurance capacity; Genetic animal model; Metabolism; Skeletal muscle

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CITRATE SYNTHASE; GLYCOGEN; SUCCINATE DEHYDROGENASE;

ANIMAL; ARTICLE; CYTOLOGY; ENDURANCE; EXERCISE TOLERANCE; FAST MUSCLE FIBER; GENETICS; MALE; METABOLISM; MOUSE; MOUSE MUTANT; OXIDATION REDUCTION REACTION; PHENOTYPE; PHYSIOLOGY; SKELETAL MUSCLE; SLOW MUSCLE FIBER; VASCULARIZATION;

ANIMALS; CITRATE (SI)-SYNTHASE; EXERCISE TOLERANCE; GLYCOGEN; MALE; MICE; MICE, KNOCKOUT; MUSCLE FIBERS, FAST-TWITCH; MUSCLE FIBERS, SLOW-TWITCH; MUSCLE, SKELETAL; OXIDATION-REDUCTION; PHENOTYPE; PHYSICAL ENDURANCE; RECEPTORS, ADRENERGIC, BETA-2; SUCCINATE DEHYDROGENASE;

EID: 84868515579     PISSN: 09057188     EISSN: 16000838     Source Type: Journal    
DOI: 10.1111/j.1600-0838.2012.01519.x     Document Type: Article

References (41)

1. Aigner A. [Performance modification in sports by beta receptor blockers]. Wien Med Wochenschr 1990: 140: 163-170.
2. Beloka S, Gujic M, Deboeck G, Niset G, Ciarka A, Argacha JF, Adamopoulos D, van de Borne P, Naeije R. Beta-adrenergic blockade and metabo-chemoreflex contributions to exercise capacity. Med Sci Sports Exerc 2008: 40: 1932-1938.
3. Bricout VA, Serrurier BD, Bigard AX. Clenbuterol treatment affects myosin heavy chain isoforms and MyoD content similarly in intact and regenerated soleus muscles. Acta Physiol Scand 2004: 180: 271-280.
4. Brooke MH, Kaiser KK. Muscle fiber types: how many and what kind? Arch Neurol 1970: 23: 369-379.
5. Brum PC, Kosek J, Patterson A, Bernstein D, Kobilka B. Abnormal cardiac function associated with sympathetic nervous system hyperactivity in mice. Am J Physiol Heart Circ Physiol 2002: 283: H1838-H1845.
6. Burniston JG, McLean L, Beynon RJ, Goldspink DF. Anabolic effects of a non-myotoxic dose of the beta2-adrenergic receptor agonist clenbuterol on rat plantaris muscle. Muscle Nerve 2007: 35: 217-223.
7. Busquets S, Figueras MT, Fuster G, Almendro V, Moore-Carrasco R, Ametller E, Argiles JM, Lopez-Soriano FJ. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res 2004: 64: 6725-6731.
8. Chruscinski AJ, Rohrer DK, Schauble E, Desai KH, Bernstein D, Kobilka BK. Targeted disruption of the beta2 adrenergic receptor gene. J Biol Chem 1999: 274: 16694-16700.
9. Crabtree B, Leech AR, Newsholme EA. Measurement of enzyme activities in crude extracts of tissues. North-Holland: Elsevier, 1979; 1-37
10. Curi R, Newsholme P, Newsholme EA. Intracellular distribution of some enzymes of the glutamine utilisation pathway in rat lymphocytes. Biochem Biophys Res Commun 1986: 138: 318-322.
11. Elfellah MS, Dalling R, Kantola IM, Reid JL. Beta-adrenoceptors and human skeletal muscle characterisation of receptor subtype and effect of age. Br J Clin Pharmacol 1989: 27: 31-38.
12. Ferreira JC, Rolim NP, Bartholomeu JB, Gobatto CA, Kokubun E, Brum PC. Maximal lactate steady state in running mice: effect of exercise training. Clin Exp Pharmacol Physiol 2007: 34: 760-765.
13. Gehrig SM, Koopman R, Naim T, Tjoakarfa C, Lynch GS. Making fast-twitch dystrophic muscles bigger protects them from contraction injury and attenuates the dystrophic pathology. Am J Pathol 2010: 176: 29-33.
14. Balmain JH, Biggers J, Claringbold P. Micromethod for the Estimation of Glycogen in the Genital Organs of the Mouse. Aust J Biol Sci 1956: 9: 139-146.
15. Harcourt LJ, Schertzer JD, Ryall JG, Lynch GS. Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue. Neuromuscul Disord 2007: 17: 47-55.
16. Helenius IJ, Tikkanen HO, Sarna S, Haahtela T. Asthma and increased bronchial responsiveness in elite athletes: atopy and sport event as risk factors. J Allergy Clin Immunol 1998: 101: 646-652.
17. Hinkle RT, Hodge KM, Cody DB, Sheldon RJ, Kobilka BK, Isfort RJ. Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor. Muscle Nerve 2002: 25: 729-734.
18. Jensen J, Brennesvik EO, Bergersen H, Oseland H, Jebens E, Brors O. Quantitative determination of cell surface beta-adrenoceptors in different rat skeletal muscles. Pflugers Arch 2002: 444: 213-219.
19. Kim YS, Sainz RD, Molenaar P, Summers RJ. Characterization of beta 1- and beta 2-adrenoceptors in rat skeletal muscles. Biochem Pharmacol 1991: 42: 1783-1789.
20. Kline WO, Panaro FJ, Yang H, Bodine SC. Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol. J Appl Physiol 2007: 102: 740-747.
21. Koopman R, Gehrig SM, Leger B, Trieu J, Walrand S, Murphy KT, Lynch GS. Cellular mechanisms underlying temporal changes in skeletal muscle protein synthesis and breakdown during chronic {beta}-adrenoceptor stimulation in mice. J Physiol 2010: 588: 4811-4823.
22. Lo S, Russell JC, Taylor AW. Determination of glycogen in small tissue samples. J Appl Physiol 1970: 28: 234-236.
23. Lynch GS, Ryall JG. Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev 2008: 88: 729-767.
24. Maltin CA, Jones P, Mantle D. Effect of protease inhibitors and clenbuterol on the in vitro degradation of dystrophin by endogenous proteases in human skeletal muscle. Biosci Rep 1993: 13: 159-167.
25. Moore NG, Pegg GG, Sillence MN. Anabolic effects of the beta 2-adrenoceptor agonist salmeterol are dependent on route of administration. Am J Physiol 1994: 267: E475-E484.
26. Nachlas MM, Tsou KC, de Souza E, Cheng CS, Seligman AM. Cytochemical demonstration of succinic dehydrogenase by the use of a new p-nitrophenyl substituted ditetrazole. J Histochem Cytochem 1957: 5: 420-436.
27. Nystad W, Harris J, Borgen JS. Asthma and wheezing among Norwegian elite athletes. Med Sci Sports Exerc 2000: 32: 266-270.
28. Reeds PJ, Hay SM, Dorwood PM, Palmer RM. Stimulation of muscle growth by clenbuterol: lack of effect on muscle protein biosynthesis. Br J Nutr 1986: 56: 249-258.
29. Robinson MM, Richards JC, Hickey MS, Moore DR, Phillips SM, Bell C, Miller BF. Acute {beta}-adrenergic stimulation does not alter mitochondrial protein synthesis or markers of mitochondrial biogenesis in adult men. Am J Physiol Regul Integr Comp Physiol 2010: 298: R25-R33.
30. Ryall JG, Plant DR, Gregorevic P, Sillence MN, Lynch GS. Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats. J Physiol 2004: 555: 175-188.
31. Ryall JG, Schertzer JD, Lynch GS. Attenuation of age-related muscle wasting and weakness in rats after formoterol treatment: therapeutic implications for sarcopenia. J Gerontol A Biol Sci Med Sci 2007: 62: 813-823.
32. Ryall JG, Sillence MN, Lynch GS. Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. Br J Pharmacol 2006: 147: 587-595.
33. Sillau AH, Banchero N. Visualization of capillaries in skeletal muscle by the ATPase reaction. Pflugers Arch 1977: 369: 269-271.
34. Turgeman T, Hagai Y, Huebner K, Jassal DS, Anderson JE, Genin O, Nagler A, Halevy O, Pines M. Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone. Neuromuscul Disord 2008: 18: 857-868.
35. van Baak MA, Mayer LH, Kempinski RE, Hartgens F. Effect of salbutamol on muscle strength and endurance performance in nonasthmatic men. Med Sci Sports Exerc 2000: 32: 1300-1306.
36. van Mil HG, Kerkhof CJ, Siegenbeek van Heukelom J. Modulation of the isoprenaline-induced membrane hyperpolarization of mouse skeletal muscle cells. Br J Pharmacol 1995: 116: 2881-2888.
37. Vieira NM, Bueno CR, Jr, Brandalise V, Moraes LV, Zucconi E, Secco M, Suzuki MF, Camargo MM, Bartolini P, Brum PC, Vainzof M, Zatz M. SJL dystrophic mice express a significant amount of human muscle proteins following systemic delivery of human adipose-derived stromal cells without immunosuppression. Stem Cells 2008: 26: 2391-2398.
38. Wolfarth B, Rankinen T, Muhlbauer S, Scherr J, Boulay MR, Perusse L, Rauramaa R, Bouchard C. Association between a beta2-adrenergic receptor polymorphism and elite endurance performance. Metabolism 2007: 56: 1649-1651.
39. Wolfarth B, Wuestenfeld JC, Kindermann W. Ergogenic effects of inhaled beta2-agonists in non-asthmatic athletes. Endocrinol Metab Clin North Am 2010: 39: 75-87, ix.
40. Yang YT, McElligott MA. Multiple actions of beta-adrenergic agonists on skeletal muscle and adipose tissue. Biochem J 1989: 261: 1-10.
41. Zeman RJ, Ludemann R, Easton TG, Etlinger JD. Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a beta 2-receptor agonist. Am J Physiol 1988: 254: E726-E732.